GKOS: Momentum From Recent Regulatory Wins Will Drive Outperformance Through 2026

Key Takeaways

• Innovative glaucoma therapies and global expansion efforts position the company for sustained revenue growth and reduced reliance on a single product.
  
• Emphasis on minimally invasive solutions and payer adoption strengthens long-term profitability and supports increased market share.
  
• Market share and profit growth are threatened by rising competition, reimbursement challenges, product launch risks, high investment costs, and external healthcare policy headwinds.

Catalysts

An ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.

• Strong ongoing adoption and utilization of iDose TR, a first-of-its-kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies-a substantial long-term opportunity given the aging population and rising prevalence of glaucoma, likely driving robust multi-year revenue and market expansion.
  
• Glaukos' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.
  
• Global scaling of commercial and market access teams, international infrastructure expansion, and upcoming launches in underpenetrated markets (such as the EU clearance and launch of iStent infinite) are expected to drive increased international sales, supporting double-digit revenue growth and further margin leverage through operational efficiencies.
  
• Increasing penetration into payer coverage for iDose (with 50%+ of commercial/Medicare lives already covered and others expected to follow) and ongoing margin improvement from higher iDose mix (83% gross margin in Q2) support the potential for sustained net margin and earnings growth as reimbursement solidifies and the product mix shifts toward higher-margin, minimally invasive solutions.
  
• The accelerating migration toward minimally invasive and in-office procedures (e.g., iDose TR, future office-based versions) aligns with the broad medical trend favoring lower-risk, outpatient therapies; this is expected to drive enduring physician and patient adoption, increase procedure volume, and improve utilization rates while also potentially reducing cost pressures and enhancing profitability longer term.

Glaukos Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Glaukos's revenue will grow by 24.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from -30.7% today to 11.1% in 3 years time.
• Analysts expect earnings to reach $132.4 million (and earnings per share of $2.14) by about August 2029, up from -$188.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $211.3 million in earnings, and the most bearish expecting $73.7 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 117.7x on those 2029 earnings, up from -58.2x today. This future PE is greater than the current PE for the US Medical Equipment industry at 26.0x.
• Analysts expect the number of shares outstanding to grow by 2.7% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.49%, as per the Simply Wall St company report.

Risks

• Increasing competition from both established device makers and new entrants in the minimally invasive glaucoma surgery (MIGS) and procedural pharmaceutical space may erode Glaukos' market share, which creates risk to long-term revenue growth and top-line expansion.
  
• The company is exposed to ongoing and potential future reimbursement pressure-including possible cuts to physician fees for ophthalmic procedures from CMS and slow professional fee adoption by certain key Medicare Administrative Contractors (MACs)-which could negatively impact pricing power, procedure volumes, and net margins.
  
• Adverse or delayed outcomes in clinical trials, regulatory reviews, or product launches (e.g., delayed FDA reimplantation decision for iDose, transition from Photrexa to Epioxa, or slower than expected rollout of new devices) could disrupt anticipated revenue streams and weigh on earnings into the medium term.
  
• The heavy investment required for R&D, marketing, advocacy, operating infrastructure, and international expansion, combined with methodical and sometimes unpredictable payer and reimbursement uptake, may constrain margin and operating leverage, potentially limiting net cash flow generation and profitability.
  
• Secular risks such as potential healthcare cost-containment policy, shifts in CMS reimbursement methodologies, or global macroeconomic instability could reduce demand for elective and interventional ophthalmic procedures, introduce volatility to Glaukos' revenues, and hamper long-term profit growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $196.46 for Glaukos based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $225.0, and the most bearish reporting a price target of just $172.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $132.4 million, and it would be trading on a PE ratio of 117.7x, assuming you use a discount rate of 7.5%.
• Given the current share price of $185.62, the analyst price target of $196.46 is 5.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.